Novartis (NYSE:NVS - Get Free Report) will be issuing its quarterly earnings data before the market opens on Tuesday, October 29th. Analysts expect the company to announce earnings of $1.91 per share for the quarter.
Novartis Price Performance
Shares of NVS traded down $1.41 during mid-day trading on Tuesday, reaching $114.32. The company had a trading volume of 858,461 shares, compared to its average volume of 1,338,813. The company has a market capitalization of $233.67 billion, a price-to-earnings ratio of 14.47, a P/E/G ratio of 1.70 and a beta of 0.57. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.72 and a current ratio of 0.93. The company's 50 day simple moving average is $116.39 and its 200 day simple moving average is $108.22. Novartis has a 1-year low of $92.19 and a 1-year high of $120.92.
Analyst Ratings Changes
Several research analysts have recently issued reports on NVS shares. Jefferies Financial Group downgraded shares of Novartis from a "buy" rating to a "hold" rating in a report on Tuesday, September 3rd. Bank of America downgraded Novartis from a "buy" rating to a "neutral" rating and dropped their target price for the company from $135.00 to $130.00 in a research report on Wednesday, September 11th. Barclays upgraded Novartis to a "strong sell" rating in a report on Monday, June 24th. The Goldman Sachs Group reiterated a "neutral" rating and issued a $121.00 price objective (up previously from $119.00) on shares of Novartis in a report on Thursday, September 5th. Finally, Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Novartis in a research report on Friday, July 19th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $120.70.
Get Our Latest Stock Analysis on Novartis
Novartis Company Profile
(
Get Free Report)
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
See Also
Before you consider Novartis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novartis wasn't on the list.
While Novartis currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
